RNA-based Oncology Biomarker Market Landscape

Secondary Research

• Conducted de-novo analysis of rearrangements and GEP biomarkers, technologies, and indications from publications / abstracts 
• Extracted rearrangement and GEP biomarker data from clinical trials and profiled commercial rearrangement / gene expression assays;
• Tiered biomarkers into low, mid, and high priority based on overall presence and inclusion in guidelines, publications, and clinical trials

‍Primary Research

• Conducted telephone interviews with oncologists, hematologists,  pathologists, laboratory directors, pharma experts, and technology KOLs to gather insights about current RNA biomarker use, vendor perceptions, selection criteria, and future trends
• Interviews were split evenly between rearrangement and GEP focus and represented community hospitals, academic medical centers, pharma, and diagnostics

‍

DeciBio delivered an in-person presentation to a client team, with the results of the analysis synthesized for understanding current patterns and future trends in RNA-based oncology biomarkers

DeciBio delivered Excel databases of findings and analyses of: 

• Rearrangement / GEP biomarker data from clinical trials
• Rearrangement and GEP genes / signatures from commercial assays
• Commercial rearrangement and GEP assay profiles, including technology, plex, interviewee satisfaction scores, and competitive differentiation

‍